UTHR (unither.com) Earnings per share growth this year

United Therapeutics combines strategic xenotransplantation alliances with steady demand for hypertension therapy. The annual change in EPS clearly demonstrates the business's reaction to market challenges, with the indicator reaching -11.60. A commitment to ESG principles is reflected in the construction of energy-efficient, net-zero carbon laboratories.
Financial and market metric breakdowns for unither.com (UTHR)
- stock value and consensus price forecast:
- business market valuation indicators:
- book capitalization information:
- debt and solvency information:
All Debt to Shareholders' Equity Ratio United Therapeutics|UTHR - Long-Term Debt to Capital|Short-Term Debt to Capital United Therapeutics Corp|UTHR - Company Debts|Debt to Net Assets Ratio United Therapeutics Corporation|UTHR - Company Long-Term Debt|Company Current Liabilities United Therapeutics|Quick Ratio unither.com
- net income and valuation multiples indicators:
UTHR - Net Income|Projected Future Earnings United Therapeutics|UTHR - Price to Earnings Ratio|Price to Future Earnings Ratio United Therapeutics|UTHR - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio United Therapeutics Corp|UTHR - Operating profit before deduction of amortization|Earnings per share for the last four quarters United Therapeutics|UTHR - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months unither.com|UTHR - Earnings growth in current year|Projected earnings per share growth rate for next year United Therapeutics
- revenue and sales proceeds data:
Basic company analysis:United Therapeutics Inc. (UTHR)

Professional managers utilize earnings per share dynamics to distinguish sustainable businesses from overvalued assets. This indicator measures the annual change in net income, reflecting the ability of United Therapeutics (UTHR) to convert its monopoly in the orphan disease niche into real growth of shareholder equity, as clearly evidenced by the year-over-year EPS growth rates.
Main competitors
Earnings per share growth rate in current year Vertex Pharmaceuticals Inc. (VRTX)|ALNY (Alnylam) - Earnings growth in current year|Earnings per share growth this year INSM (Insmed)|Net earnings per share growth this year BMRN (BioMarin)|BBIO (BridgeBio Pharma) - Earnings per share increase in current year|Earnings growth in current year BGM (BGM Group Ltd)|COGT (Cogent Bio) - Earnings per share trend in current year|Xeris Biopharma - Earnings growth in current year|Earnings per share increase in current year KROS (Keros Therapeutics)|ARCT: Earnings growth in current year|Eton Pharmaceuticals Inc (ETON) - Earnings growth in current year|Earnings per share growth in current year Kamada Corp|FULC: Earnings per share increase in current year|Earnings per share growth in current year Abeona Therapeutics, Inc. (ABEO)|Net earnings per share growth this year Mereo BioPharma Group plc MREO|Earnings per share growth in current year Protalix BioTherapeutics PLX|Earnings growth in current year Pliant Therapeutics PLRX|appliedtherapeutics.com - Earnings growth in current year|Earnings per share increase in current year RNTX (Rein Therapeutics, Inc.)|GELS: Earnings growth in current year|Earnings per share growth rate in current year Aytu BioPharma, Inc. (AYTU)|CMMB (Chemomab Therapeutics Ltd) - Earnings growth in current year|Earnings per share growth this year SRXH (SRx Health Solutions)|Net earnings per share growth this year PLRZ (Polyrizon Ltd)|AEZS - Earnings per share growth rate in current year|Earnings per share growth in current year Cyclo Therapeutics Inc. CYTH|Inozyme Pharma, Inc. (INZY) - Earnings per share growth rate in current year|RPHM: Net earnings per share growth this year|Earnings per share growth rate in current year COSCIENS Biopharma Inc